Such approaches have been shown to be efficacious in treatment of breast and ovarian cancers of BRCA1/2 carriers [60,61,62,63,64,65,66], as well pancreatic cancers with an inactivation of BRCA1, BRCA2, or PALB2 and an HR deficiency tumor mutation signature [67]. This evidence concerns the gene PALB2 and neoplasm.